TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PoCE at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: TLF at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: IC-50 value of nab-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell invasive ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average food intake of nude mice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived disability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: model efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal Anemia Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: annualized relapse rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEDA-3 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HAM-D17 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inappropriate revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: median full‐force daily crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: faecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six-minute walking test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in arm curl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: gains in chair stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sIgA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EED scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microbiota α-diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dorsiflexion stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Balance function (Pro-Kin test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: success rate of screw placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: accuracy rate of screw placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychosocial quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity for finding CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of potentially inappropriate medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance rate of deprescribing interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost saved per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete response (CR) percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma level of TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: P‐wave dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sleep quality ratings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: FCA (Femoral Component Angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: self-reported adequate relief rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in global symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rapid eye movement sleep proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean core body temperature (CBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rCBV in the infarct core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with at least 1 major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Propofol infusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCP‐16 subscales scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rule out patients without cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable neurological outcome (modified Rankin Score ≤ 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diversity of the mucosal microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of beneficial bacterial taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of harmful bacterial taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MSQ Role‐Function‐Restrictive score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in MIDAS total scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in EQ-5D-5L visual analog scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Normalization of IGF‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GH levels maintained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median time to loss of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: RSV serum‐neutralizing responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tic-related impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in occupational health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain intensity during heel prick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sites with PD ≥ 5 mm and BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the NAPSI scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biochemical parameters (serum calcium, potassium, zinc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sinonasal surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in need for in-study SCS use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in Sinonasal Outcome Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time with gastric pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean time with gastric pH >6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Muscle loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of nutritional targets (protein and energy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation for glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative risk of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Survival with good neurologic outcome at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Neurologic recovery at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac recovery at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse kidney events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: KSS-Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: KSS-Expectation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VSCs production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in PrEP care at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access to PrEP medications greater than 80% of study days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Responder rate for enterosgel versus placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerable pain (NRS ≤3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall joint health measured by WOMAC total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee joint pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peripheral nerve cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sexual health concerns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antipsychotic adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalization incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high‐sensitivity C‐reactive protein (hs‐CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tumor necrosis factor‐alpha (TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin ‐6 (IL‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of the LASSO-model for screening of trisomy 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDVT occurrence prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS snoring score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopment in childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS score on general satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS score on oral health status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS score on psychological discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in submental fat rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ≥1-grade reduction in submental fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E2 production per follicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BMD loss prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of RANKL expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid- or cholesterol-related parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognostic prediction using C-index
Endpoint domain: Mortality/survival
Primary endpoint: Time to achieve pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monofollicular development rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Constant subjective score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SANE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A/P ROM elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative residual edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Perceived role limitations due to emotional health problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in FACIT-F
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in PSQI total
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in HADS anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: inflammation periodontal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCLs (salivary stress levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total analgesic effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total equivalent morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QLQ-C30 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hazardous drinking rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol consumption at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in providing pain-free treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screen failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Fewer negative events
Endpoint domain: Adverse events/effects
Primary endpoint: clinical efficacy advantage of 40U daxibotulinumtoxinA over 20U onabotulinumtoxinA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDRS17-2.69
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual fatigue symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of urinary incontinence three months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postvaccination titer ≥ 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: myodynamia of the affected limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological deficit degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily living ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom controllability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant symptoms of GAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant sleep difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicted forced expiratory volume in 1 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Predicted forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean number of exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Scores of STAI-S
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ≥ 90% improvement in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ≥ 5‐point reduction in Short Form‐36 physical and mental component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in out-of-pocket costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Willingness to perform CPR on a stranger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Theoretical knowledge retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dissemination of CPR awareness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: risky sex intentions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVLT-R recognition-discrimination index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HVLT-R total recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: acceptability of cognitive-behavioural therapy intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immediate endovascular treatment decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain scores
Primary endpoint: Forty-item questionnaire total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hypertension control at year 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Feeding Skills Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement of fasting blood sugar (FBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of peripheral blood EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical response to FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ISWT distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance and walking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA surface area with periodicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LA periodicity CL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3D deviations at the implant platform and apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total adenomas per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adenomas per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fall prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ASCVD events
Endpoint domain: Mortality/survival
Primary endpoint: cardiac anxiety improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean axial displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum 25 hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2 h postprandial blood glucose (2hPBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycosylated hemoglobin (HbAlc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: worsening of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement after restarting AChEI medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver's mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CDI recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: associated complications
Endpoint domain: Adverse events/effects
Primary endpoint: time to first bowel motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to tolerance of solid food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vitality domain score of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with treatment (Likert scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death or cardiovascular rehospitalization
Endpoint domain: Mortality/survival